Article
Multidisciplinary Sciences
Dominique F. Leitner, Evgeny Kanshin, Manor Askenazi, Yik Siu, Daniel Friedman, Sasha Devore, Drew Jones, Beatrix Ueberheide, Thomas Wisniewski, Orrin Devinsky
Summary: This pilot study found that short-term everolimus before epilepsy surgery in TSC and FCD resulted in no adverse events and trending lower mTOR signaling (phospho-S6). Future studies should evaluate implications of our findings, including coagulation system activation and everolimus efficacy in FCD, in larger studies with long-term treatment to better understand molecular and clinical effects.
Article
Biochemistry & Molecular Biology
Ahlem Jebali, Maxime Battistella, Celeste Lebbe, Nicolas Dumaz
Summary: The network involving PI3K, AKT, and mTOR is important in melanoma oncogenesis, with RICTOR overexpression associated with poor prognosis. RICTOR enhances melanoma-initiating cells with stemness properties and contributes to resistance to BRAF inhibitors. An interaction between RICTOR and STAT3 in resistant cells, as well as a connection between RAS and RICTOR in resistant melanoma, were identified, suggesting RICTOR as a valuable therapeutic target in melanoma.
Article
Oncology
Yuma Shibutani, Shinya Suzuki, Atsunobu Sagara, Tomohiro Enokida, Susumu Okano, Takao Fujisawa, Fumiaki Sato, Tetsuro Yumoto, Motohiko Sano, Toshikatsu Kawasaki, Makoto Tahara
Summary: This retrospective study evaluated the association between lenvatinib-induced proteinuria and renal function in patients with thyroid cancer. The results showed that the degree of proteinuria was not associated with renal function. Therefore, treatment with lenvatinib should be continued with attention to renal function, regardless of the degree of proteinuria.
FRONTIERS IN ONCOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Antonino Glaviano, Aaron S. C. Foo, Hiu Y. Lam, Kenneth C. H. Yap, William Jacot, Robert H. Jones, Huiyan Eng, Madhumathy G. Nair, Pooyan Makvandi, Birgit Geoerger, Matthew H. Kulke, Richard D. Baird, Jyothi S. Prabhu, Daniela Carbone, Camilla Pecoraro, Daniel B. L. Teh, Gautam Sethi, Vincenzo Cavalieri, Kevin H. Lin, Nathalie R. Javidi-Sharifi, Eneda Toska, Matthew S. Davids, Jennifer R. Brown, Patrizia Diana, Justin Stebbing, David A. Fruman, Alan P. Kumar
Summary: The PI3K/AKT/mTOR (PAM) signaling pathway plays a crucial role in cell survival, growth, and cell cycle progression. Dysregulation of this pathway is associated with cancer development and resistance to therapy. This review focuses on the major dysregulations in the PAM signaling pathway in cancer and discusses strategies for overcoming treatment resistance. The role of PAM signaling in immunology and immunotherapies is also discussed.
Review
Cell Biology
Ido Rippin, Hagit Eldar-Finkelman
Summary: Neurodegenerative disorders pose a significant threat to public health globally, with a lack of effective treatment options. Research indicates that GSK-3 plays a crucial role in regulating mood behavior, cognitive functions, and neuron viability, potentially serving as a common target for therapeutic interventions in these disorders.
Review
Oncology
Wojciech Wiese, Julia Barczuk, Olga Racinska, Natalia Siwecka, Wioletta Rozpedek-Kaminska, Artur Slupianek, Radoslaw Sierpinski, Ireneusz Majsterek
Summary: The PI3K/Akt/mTOR pathway is crucial in cancer development and can be a potential therapeutic target for leukemia. Recent research indicates that inhibition of this pathway may lead to improved treatment outcomes for leukemia.
Review
Biochemistry & Molecular Biology
Beibei Mao, Qi Zhang, Li Ma, Dong-Sheng Zhao, Pan Zhao, Peizheng Yan
Summary: The mammalian target of rapamycin (mTOR) is a crucial protein kinase involved in various cellular processes. Inhibitors of mTOR have shown antiviral, anti-inflammatory, and antiproliferative effects and have been applied in the research of different diseases.
Article
Pharmacology & Pharmacy
Mahak Arora, Nikolina Kutinova Canova, Hassan Farghali
Summary: This review provides a brief overview of the mechanism behind the progression of non-alcoholic fatty liver disease (NAFLD) to chronic non-alcoholic steatohepatitis (NASH), liver cirrhosis, and hepatocellular cancer. The review highlights the potential of targeting mTOR as a treatment for NASH, due to its significant role in lipogenesis and alleviating inflammation and fibrosis.
EUROPEAN JOURNAL OF PHARMACOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Eleni A. Karatrasoglou, Maria Dimou, Alexia Piperidou, Eleftheria Lakiotaki, Penelope Korkolopoulou, Theodoros P. Vassilakopoulos
Summary: This review focuses on discussing the oncogenic mechanisms of the PI3K/v-akt/mTOR pathway in B cell non-Hodgkin lymphoma (NHL), and summarizes the clinical applications of mTOR inhibitors in B cell NHLs.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Oncology
Abdelhakim Bouyahya, Aicha El Allam, Sara Aboulaghras, Saad Bakrim, Naoual El Menyiy, Mohammed Merae Alshahrani, Ahmed Abdullah Al Awadh, Taoufiq Benali, Learn-Han Lee, Nasreddine El Omari, Khang Wen Goh, Long Chiau Ming, Mohammad S. Mubarak
Summary: This review provides an overview of the recent developments in the mTOR signaling pathway and its molecular involvement in various human cancer types, as well as the research progress of different mTOR inhibitors and their rational combinations with immunotherapies.
Review
Chemistry, Medicinal
Patrik Oleksak, Eugenie Nepovimova, Zofia Chrienova, Kamil Musilek, Jiri Patocka, Kamil Kuca
Summary: Mechanistic target of rapamycin (mTOR) is a protein kinase that regulates cell functions. Dysregulation of mTOR activity is associated with various pathological conditions. Inhibition of overactivated mTOR is a rational approach for treating human diseases. Rapamycin is a natural inhibitor of mTOR with antitumor and immunosuppressive activity. Different generations of mTOR inhibitors have been developed, including rapalogs, mTOR kinase inhibitors, and dual PI3K/mTOR inhibitors. Novel inhibitors are still being developed to better understand the role of mTOR in signaling pathways and human diseases.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2022)
Review
Cell Biology
Wei Xiao, Juan Li, June Hu, Lingzhi Wang, Jiang-Rong Huang, Gautam Sethi, Zhaowu Ma
Summary: circRNAs, a type of non-coding RNA characterized by high abundance and cell-specific expression, play crucial roles in regulating the cell cycle and biological processes through various mechanisms of gene expression regulation.
CELL PROLIFERATION
(2021)
Article
Chemistry, Medicinal
Tian Xu, Jifa Zhang, Chengcan Yang, Ryszard Pluta, Guan Wang, Tinghong Ye, Liang Ouyang
Summary: This study identified a potential compound for treating triple negative breast cancer by screening mTOR inhibitors and studying their related activities. The compound was found to induce apoptosis and autophagic cell death in cancer cells, providing new insights for future drug development for TNBC treatment.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2021)
Review
Oncology
Aleksandra Derwich, Monika Sykutera, Barbara Brominska, Miroslaw Andrusiewicz, Marek Ruchala, Nadia Sawicka-Gutaj
Summary: This review investigates the expression of mTOR gene and protein in papillary thyroid cancer (PTC) and their relationship with PTC risk and clinical outcome. It also reviews the use of mTOR inhibitors and potential targeted therapies in PTC. The results of previous studies are summarized, and future research directions are suggested.
Article
Oncology
Anubhav G. Amin, Seung Won Jeong, John L. Gillick, Tolga Sursal, Raj Murali, Chirag D. Gandhi, Meena Jhanwar-Uniyal
Summary: Selective ATP-competitive dual inhibitors of mTORC1 and mTORC2, Torin1, Torin2, and XL388, showed concentration-dependent pharmacodynamic effects in suppressing tumor cell migration, proliferation, and cell cycle progression. Among them, Torin2 exhibited the strongest inhibitory effects on both mTORC1 and mTORC2, suggesting its potential as an effective treatment for glioblastoma and overcoming drug resistance.
INTERNATIONAL JOURNAL OF ONCOLOGY
(2021)
